Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

David J. VanderWeele · SciRah

Researcher profile · Semantic Scholar

David J. VanderWeele

Share profile

David J. VanderWeele — researcher profile on SciRah

h-index: 23
Works: 118
Citations: 1,985

Most-cited papers

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
F. Karzai, David J. VanderWeele, R. Madan, H. Owens +23 more
2018Journal of Immunotherapy for Cancer270 citations Open access
Semantic Scholar
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.
D. Spratt, S. Srinivas, Nabil Adra, Bilawal Ahmed +36 more
2025The Journal of the National Comprehensive Cancer Network133 citations
Semantic Scholar
Past, Current, and Future of Immunotherapies for Prostate Cancer
Adeline N. Boettcher, A. Usman, A. Morgans, David J. VanderWeele +2 more
2019Frontiers in Oncology103 citations Open access
Semantic Scholar
Accelerating precision medicine in metastatic prostate cancer
J. Mateo, R. McKay, W. Abida, R. Aggarwal +26 more
2020Nature Cancer77 citations Open access
Semantic Scholar
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy
S. Wilkinson, Huihui Ye, F. Karzai, S. Harmon +24 more
2020medRxiv72 citations Open access
Semantic Scholar
Quantitative Multiparametric MRI Features and PTEN Expression of Peripheral Zone Prostate Cancer: A Pilot Study.
S. McCann, Yu-Lei Jiang, Xiao-Bing Fan, Jianing Wang +4 more
2016AJR. American journal of roentgenology53 citations Open access
Semantic Scholar
Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor
Remi Adelaiye-Ogala, B. Gryder, Yen Thi Minh Nguyen, A. Alilin +9 more
2019Molecular Cancer Therapeutics49 citations Open access
Semantic Scholar
Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer
Marc Gillard, J. Lack, A. Pontier, D. Gandla +6 more
2017European Urology Focus41 citations Open access
Semantic Scholar
Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
J. de Bono, L. Fong, T. Beer, Xinrong Gao +9 more
202134 citations
Semantic Scholar
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.
T. Gilligan, Daniel W. Lin, N. Adra, A. Bagrodia +31 more
2025The Journal of the National Comprehensive Cancer Network33 citations
Semantic Scholar
A case report of multiple primary prostate tumors with differential drug sensitivity
S. Wilkinson, S. Harmon, Nicholas T. Terrigino, F. Karzai +17 more
2020Nature Communications30 citations Open access
Semantic Scholar
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy
David J. VanderWeele, R. Finney, K. Katayama, Marc Gillard +17 more
2018European Urology Focus30 citations Open access
Semantic Scholar
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response
F. Karzai, S. Walker, S. Wilkinson, R. Madan +21 more
2020Clinical Cancer Research29 citations Open access
Semantic Scholar
Circulating tumor cells capture disease evolution in advanced prostate cancer
J. Lack, Marc Gillard, Maggie Cam, G. Paner +1 more
2017Journal of Translational Medicine28 citations Open access
Semantic Scholar
Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer
Edwin E. Reyes, Marc Gillard, Ryan Duggan, K. Wroblewski +7 more
2015Journal of Translational Science23 citations
Semantic Scholar
Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy
Abu Baker, Jochen H. Lorch, David J. VanderWeele, Bin Zhang
2023Pharmaceutics18 citations Open access
Semantic Scholar
A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with Metastatic Castration Resistant Prostate Cancer
Rahul R. Aggarwal, J. Vuky, David J. VanderWeele, Matthew B. Rettig +16 more
2025Journal of Clinical Oncology14 citations
Semantic Scholar
Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).
R. Aggarwal, J. Vuky, David J. VanderWeele, M. Rettig +10 more
2022Journal of Clinical Oncology14 citations
Semantic Scholar
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
M. Hussain, M. Kocherginsky, Parminder Singh, Zin W. Myint +6 more
2023Journal of Clinical Oncology13 citations
Semantic Scholar
CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
Arpit Rao, C. Ryan, David J. VanderWeele, G. Heller +7 more
202112 citations
Semantic Scholar
Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
Sarah E. Fenton, David J. VanderWeele
2023Frontiers in Oncology11 citations Open access
Semantic Scholar
A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183).
Joshua J. Meeks, A. Shilatifard, Stephen D. Miller, A. Morgans +3 more
202011 citations
Semantic Scholar
Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
David J. VanderWeele, E. Antonarakis, M. Carducci, R. Dreicer +7 more
2019Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small
A. Serritella, H. Beltran, T. Lotan, David J. VanderWeele +3 more
2024The Oncologist9 citations Open access
Semantic Scholar
Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue.
Marc Gillard, Westin R Tom, T. Antic, G. Paner +2 more
2015American journal of translational research9 citations
Semantic Scholar
mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy
Samuel A. Gold, David J. VanderWeele, S. Harmon, Jonathan B Bloom +13 more
2019Urologic oncology8 citations Open access
Semantic Scholar
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
Arpit Rao, G. Heller, C. Ryan, David J. VanderWeele +11 more
2023Journal of Clinical Oncology6 citations
Semantic Scholar
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
David J. VanderWeele, M. Kocherginsky, Sabah Munir, B. Martone +5 more
2022Clinical Genitourinary Cancer6 citations
Semantic Scholar
PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
David J. VanderWeele, M. Hussain
2020Clinical advances in hematology & oncology : H&O6 citations
Semantic Scholar
Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.
R. Madan, F. Karzai, David J. VanderWeele, Heather H. Cheng +1 more
2023Journal of Clinical Oncology5 citations
Semantic Scholar
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
Arpit Rao, G. Heller, C. Ryan, David J. VanderWeele +11 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience
Praneet Polineni, L. Ashack, J. Kalapurakal, A. Morgans +5 more
2021Advances in Radiation Oncology5 citations Open access
Semantic Scholar
PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER
David J. VanderWeele, B. Turkbey, A. Sowalsky
2016Expert Review of Precision Medicine and Drug Development5 citations Open access
Semantic Scholar
Response to pembrolizumab in advanced prostate cancer with predictive biomarkers
Nicole J. Altomare, Yu-Tai Li, Clayton Neill, Maha Hussain +1 more
2025The Oncologist4 citations Open access
Semantic Scholar
Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate Cancer.
Nicole Handa, Eric V. Li, J. Michael, J. Proudfoot +13 more
2025European Urology Oncology4 citations
Semantic Scholar
Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression.
Tyler F. Stewart, S. E. Fenton, S. Nazari, A. Elliott +6 more
2024Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response.
Yazan Numan, Jonathan C. Zhao, Song Tang, Youbin Zhang +7 more
20203 citations
Semantic Scholar
Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.
Gang Chen, David J. VanderWeele, F. Karzai, Marijo Bilusic +13 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer
Surendra Gulla, Tej Sharma, Ephraim Gardner, Chennan Li +18 more
2026Cancer Research2 citations Open access
Semantic Scholar
Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin
J. S. Wang, J. Shapiro, Sarah Orlando, Rusul Al-Marayaty +5 more
2025Journal of Cancer Research and Clinical Oncology2 citations Open access
Semantic Scholar
Management Decisions for Metastatic Castration-resistant Prostate Cancer in 2024.
David J. VanderWeele, Maha Hussain
2024European Urology2 citations
Semantic Scholar
Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers
Cherry Au, Changtai Tian, R. Kollipara, David J. VanderWeele +3 more
2025Oncology and Translational Medicine1 citations Open access
Semantic Scholar
Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion.
E. Bent, S. McBride, Shilpa Gupta, David J. VanderWeele +11 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar
17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433)
Chet Bohac, S. Pal, R. Sweis, R. Kotecha +17 more
2025The Oncologist1 citations Open access
Semantic Scholar
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): A comparison of enzalutamide vs abiraterone acetate.
A. Morgans, Yangruijue Ma, James C. Jackson, Charles J. Ryan +5 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)
S. Pal, Randy F. Sweiss, R. Kotecha, K. Runcie +20 more
2025Molecular Cancer Therapeutics1 citations
Semantic Scholar
Abstract 1324: MECOM a novel player in AR-driven treatment resistant castration-resistant prostate cancer
Surendra Gulla, Tej Sharma, Ephraim Gardner, S. Sundar +9 more
2025Cancer Research1 citations
Semantic Scholar
Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report
Sareen T Ali, David J. VanderWeele
2024Current Oncology1 citations Open access
Semantic Scholar
A randomized phase II study of ADT + abiraterone versus ADT + abiraterone + docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer.
S. E. Fenton, Masha Kocherginsky, David J. VanderWeele, M. Hussain
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract 6356: Novel antibody targeting tumor NKG2D ligand MIC: Preclinical studies and clinical development plan for mCRPC
Jennifer D. Wu, Jeffery A. Sosman, Masha Kocherginsky, A. Serritella +2 more
2024Cancer Research1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Karzai×8
Invite
F. Karzai — researcher profile on SciRah
A. Morgans×8
Invite
A. Morgans — researcher profile on SciRah
M. Hussain×8
Invite
M. Hussain — researcher profile on SciRah
W. Dahut×7
Invite
W. Dahut — researcher profile on SciRah

×6

Invite

R. Madan — researcher profile on SciRah

Invite

J. Gulley — researcher profile on SciRah

Invite

A. Sowalsky — researcher profile on SciRah

Invite

M. Merino — researcher profile on SciRah

Invite

B. Turkbey — researcher profile on SciRah

Marc Gillard×5

Invite

Marc Gillard — researcher profile on SciRah

Marijo Bilusic×4

Invite

Marijo Bilusic — researcher profile on SciRah

Invite

S. Harmon — researcher profile on SciRah